Drugs / AR-501
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03669614 | Dec 2018 → Jul 2023 | cystic fibrosis | Aridis Pharmaceuticals, Inc. | Unknown | Met primary |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2023-03-13 | Aridis Pharmaceuticals, Inc. | Results Aridis Meets Primary and Secondary Endpoints in Phase 2a Study of AR-501 in Cystic Fibrosis Patients aridispharma.com ↗ |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2023-03-13 | Aridis Pharmaceuticals, Inc. | Aridis Meets Primary and Secondary Endpoints in Phase 2a Study of AR-501 in Cystic Fibrosis Patients aridispharma.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AR-501 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03669614 ↗ |
| Route | Inhaled | “administered via inhalation” NCT03669614 ↗ |